Matthew Diamond, DO
Nephrology · Augusta, GANPI 1760410351
Payments from drug & device makers
Across 471 payments — averaging $1729.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$550K
- Quanta Dialysis Technologies Inc$161K
- Bayer$90K
- Calliditas Therapeutics US Inc.$3K
- GSK$2K
- AstraZeneca$1K
- plus $6K from 27 others
Across 124 payments — averaging $948.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$66K
- Quanta Dialysis Technologies Inc$39K
- Eli Lilly$13K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 16 | $550,477 |
| Quanta Dialysis Technologies Inc | 5 | $160,949 |
| Bayer | 56 | $90,293 |
| Calliditas Therapeutics US Inc. | 27 | $3,488 |
| GSK | 18 | $2,061 |
| AstraZeneca(2 entities) | 62 | $1,077 |
| Amgen(2 entities) | 48 | $1,076 |
| Vifor Pharma, Inc. | 40 | $665 |
| Novartis | 17 | $632 |
| Otsuka America Pharmaceutical, Inc. | 23 | $533 |
| Mallinckrodt Hospital Products Inc. | 21 | $499 |
| Aurinia Pharma U.S., Inc. | 26 | $450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $345 |
| Fresenius USA Marketing, Inc. | 21 | $340 |
| OPKO Pharmaceuticals, LLC | 19 | $336 |
| Novo Nordisk | 4 | $262 |
| Akebia Therapeutics Inc | 8 | $181 |
| Travere Therapeutics, Inc. | 14 | $155 |
| Astrazeneca UK Limited | 1 | $135 |
| Daiichi Sankyo Inc. | 7 | $127 |
| Lilly USA, LLC | 5 | $112 |
| Boehringer Ingelheim | 3 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $53 |
| Ardelyx, Inc. | 3 | $51 |
| Mallinckrodt Enterprises LLC | 4 | $49 |
| Medline Industries LP | 1 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Merck | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Boston Scientific | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
How this compares
$814,623 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Augusta
- Harold HubertAugusta$2.8M
- Barton BrezinaAugusta$1.5M
- Laura MulloyAugusta$891K
- Devesh PatelAugusta$279K
- Don WilliamsonAugusta$116K
- Syed BabarAugusta$63K
- James StenardAugusta$13K
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.